Department of Urology, Kanagawa Cancer Center, Yokohama, Japan.
Department of Urology, Yokohama City University Hospital, Yokohama, Japan.
Asian J Endosc Surg. 2024 Apr;17(2):e13289. doi: 10.1111/ases.13289.
The number of facilities adopting intracorporeal urinary diversion (ICUD) using robots instead of extracorporeal urinary diversion (ECUD) is increasing. However, guidance on how to introduce robot-assisted radical cystectomy (RARC) + ICUD in each urological institute remains unclear. This study aimed to verify the feasibility of the transition from laparoscopic radical cystectomy (LRC) + ECUD to RARC + ICUD.
We retrospectively analyzed 26 consecutive patients who underwent ICUD with an ileal conduit after RARC between 2018 and 2020 (RARC + ICUD early group). We then compared these patients with 26 consecutive patients who underwent ECUD with an ileal conduit after LRC between 2012 and 2019 (LRC + ECUD late group) at Yokohama City University Hospital.
In the RARC + ICUD early group compared with the LRC + ECUD late group, the median total operation time was 516 versus 532.5 min (P = .217); time to cystectomy, 191 versus 206.5 min (P = .234); time of urinary diversion with an ileal conduit, 198 versus 220 min (P = .016); postoperative maximum C-reactive protein levels, 6.98 versus 12.46 mg/L (P = .001); number of days to oral intake, 3 versus 5 days (P = .003); length of hospital stay, 17 versus 32 days (P < .001). The postoperative complication rates (within 90 days) were 23.1% and 42.3% in the RARC + ICUD early and LRC + ECUD late groups, respectively (P = .237). Clavien-Dindo classification ≥3 was noted in 1 and 4 patients in the RARC + ICUD early and LRC + ECUD late groups, respectively (P = .350).
Regarding perioperative outcomes, the RARC + ICUD early group was not inferior to the LRC + ECUD late group. This study suggests the feasibility of a transition from LRC + ECUD to RARC + ICUD.
越来越多的医疗机构采用机器人进行腔内尿路分流术(ICUD),而不是传统的体外尿路分流术(ECUD)。然而,在每个泌尿科机构中,如何引入机器人辅助根治性膀胱切除术(RARC)+ICUD 仍不明确。本研究旨在验证从腹腔镜根治性膀胱切除术(LRC)+ECUD 过渡到 RARC+ICUD 的可行性。
我们回顾性分析了 2018 年至 2020 年间接受 RARC+回肠导管 ICUD 的 26 例连续患者(RARC+ICUD 早期组),并与 2012 年至 2019 年间接受 LRC+回肠导管 ECUD 的 26 例连续患者(LRC+ECUD 晚期组)进行比较。
与 LRC+ECUD 晚期组相比,RARC+ICUD 早期组的总手术时间中位数为 516 分钟与 532.5 分钟(P=0.217);膀胱切除术时间为 191 分钟与 206.5 分钟(P=0.234);回肠导管尿路分流时间为 198 分钟与 220 分钟(P=0.016);术后最高 C 反应蛋白水平为 6.98 毫克/升与 12.46 毫克/升(P=0.001);口服摄入天数为 3 天与 5 天(P=0.003);住院时间为 17 天与 32 天(P<0.001)。RARC+ICUD 早期组和 LRC+ECUD 晚期组的术后 90 天内并发症发生率分别为 23.1%和 42.3%(P=0.237)。RARC+ICUD 早期组和 LRC+ECUD 晚期组分别有 1 例和 4 例患者发生 Clavien-Dindo 分级≥3 级(P=0.350)。
在围手术期结果方面,RARC+ICUD 早期组并不劣于 LRC+ECUD 晚期组。本研究表明,从 LRC+ECUD 过渡到 RARC+ICUD 是可行的。